CTRI/2020/09/027913已完成4 期
Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadriTM) administered by the intramuscular route in participants 60 years of age and older - INCENTIVE: QIV-1
Seth GSMC and KEM Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female of no child bearing potential 60 years and above at the time of study vaccine administration.
- •2. Provide written informed consent.
- •3. The participant is willing to comply with study protocol requirements, including availability for all scheduled visits of the study.
- •4. Healthy, as determined by medical history and clinical assessment of the investigator.
排除标准
- 未提供
研究者
相似试验
尚未招募
4 期
Immunity against Influenza virus disease and safety of FluQuadri (marketed vaccine with protection against 4 types of influenza virus) in children of age between 6 and 12 monthsCTRI/2021/10/037161Seth GS Medical College and KEM Hospital
进行中（未招募）
1 期
Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years oldImmune response to infuenza vaccine in young childrenEUCTR2021-003804-42-NOHelse Bergen HF50
尚未招募
4 期
Immunity against Influenza virus disease and safety of FluQuadri (marketed vaccine with protection against 4 types of influenza virus) in children of age between 3 and 8 yearsCTRI/2021/10/037159Seth GS Medical College KEM Hospital
进行中（未招募）
1 期
Immunity to influenza virus disease and safety of Vaxigrip Tetra® (commercial vaccine with protection against 4 types of influenza virus) in participants 60 years and olderInfluenzaEUCTR2021-003307-18-BEniversity of Antwerp50
已完成
1 期
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16IRCT20190504043464N1Iran University of Medical Sciences200